Defined Immunoceuticals of the highest activity and purity for pre-clinical research and development applications
Innaxon is the experts for TLR agonists and antagonists. They develop and manufacture defined “Immunoceuticals” of the highest activity and purity for pre-clinical research and development applications for vaccine adjuvants and immuno-therapy. Their unique biological and synthetic toll-like receptor (TLR) ligands (IAXO compounds) are well-characterized and effective biological response modifiers of inappropriate or disproportionate immune responses.
Innaxon is a part of AdipoGen Life Sciences, who also cooperates with a number of other manufacturers such as: Ancell Corporation, BioActs, BioViotica, Chemodex, Chimerigen Laboratories, JaICA and South Bay Bio.
Bio-Connect Life Sciences supplies all their products in the Benelux. If you have any questions, please contact the helpdesk.
Major product lines from Innaxon
IAXO Compounds – Inhibitors of sterile inflammation
The novel IAXO compounds are synthetic TLR4/CD14 ligands with TLR4 modulating activities in vitro and conferring protection against TLR4/CD14-mediated tissue damage and inflammation in vivo. IAXOs are useful to explore CD14- dependent and TLR4-independent pathways and TLR4 activation by endogenous ligands (e.g. hyaluronic acid oligosaccharides, oxLDL, HMGB1) in sterile inflammation. IAXO compounds have been shown to inhibit neuropathic pain, secondary necrosis of acute drug-induced liver failure and vascular inflammation and abdominal aortic aneurysm by blocking non-hematopoietic TLR4 signaling. They are useful tools, where inhibition of sterile (auto-) inflammation is desired, without compromising TLR4’s key role in the defense of pathogens.
|IAXO-101 (CD14/TLR4 Antagonist) (synthetic) (IAX-600-001)|
|IAXO-102 (CD14/TLR4 Antagonist) (synthetic) (IAX-600-002)|
|IAXO-103 (CD14/TLR4 Antagonist) (synthetic) (IAX-600-003)|